Exelixis, Inc.

- No specific mention of new fundraising through debt or equity in the provided transcript. - Company emphasizes strong financial position with significant cash flows. - Capital allocation focuses on R&D, business development (BD) opportunities, and share repurchases. - Access to capital is noted, but no concrete plans for raising new funds through debt or equity disclosed. - Ongoing share repurchase program includes an additional $750 million authorization by the board. - Priority remains on disciplined investment in high-value opportunities and maintaining financial strength.

- Exelixis is allocating capital across three key areas: R&D investments, business development (BD) opportunities, and share repurchases. - The company maintains a financially strong position with significant cash flows, enabling balanced funding of these priorities. - They prioritize R&D spend continuously, funding projects that demonstrate potential, while BD activities are overseen by senior leadership for strategic opportunities. - Share repurchases are ongoing, with recent repurchases totaling approximately $430.8 million in Q1 2026 and a new $750 million stock repurchase plan authorized in May 2026, expiring December 2027. - Strategic investments focus on advancing their pipeline, especially the development and upcoming launch of zanzalitinib (ZANZA) in colorectal cancer and expansion in renal cell carcinoma and neuroendocrine tumors. - They also remain open to external innovation through targeted BD at appropriate valuations.

- CABOMETYX revenue and demand continue strong growth; Q1 2026 U.S. net product revenues grew 8% YoY to $555 million. - CABOMETYX TRx volume increased 14% in Q1 2026 vs Q1 2025, outpacing market growth (7%). - CABOMETYX gained 3 share points from 44% to 47% in the oral TKI market basket in Q1 2026. - Highest number of new patient starts ever for CABOMETYX in Q1 2026, indicating strong momentum. - Expansion of GI sales team to grow CABOMETYX's neuroendocrine tumor market share, especially in community settings. - Full launch preparation underway for ZANZA (zanzalintinib) in colorectal cancer later in 2026, representing a $1.5 billion market opportunity. - ZANZA development includes seven ongoing or upcoming pivotal trials, aiming to establish leadership in RCC and GI cancers. - Ongoing share repurchase program reflects confidence and aims to enhance shareholder value alongside R&D and BD investments.

- Exelixis reiterated full-year 2026 financial guidance (page 3), indicating confidence in stable or growing earnings. - Strong current growth with first quarter 2026 CABOMETYX U.S. net product revenues up 8% YoY to $555 million (page 1/3). - Non-GAAP net income for Q1 2026 was $232.8 million, or $0.87 per share diluted, showing profitability and momentum (page 3). - The company expects to complete a $750 million stock repurchase plan by May 2026 and has authorized a new $750 million repurchase plan through December 2027, enhancing EPS through share count reduction (page 3). - Expanding CABOMETYX market share and launch of ZANZA in colorectal cancer later in 2026 expected to drive future revenue and earnings growth (pages 1/3). - Continued R&D investments and broad clinical pipeline provide potential upside but may increase near-term expenses (pages 2/10).

The transcript provided does not include specific information regarding the current or expected orderbook or pending orders for Exelixis. The discussion primarily focuses on: - Clinical trial updates (e.g., STELLAR-303, LITESPARK studies) - Commercial strategy and market opportunities for CABOMETYX and zanzalitinib (ZANZA) - Market share gains and revenue performance of CABOMETYX - Regulatory review timelines (e.g., PDUFA date for STELLAR-303 expected early December) - Resource allocation strategies including R&D, business development, and share repurchases No explicit data on orderbook or pending orders is mentioned in the excerpt from the Q1 2026 earnings call.